Abstract: A detergent composition and a method of washing/cleaning urushiol at least partially, more typically substantially or completely off a surface of human skin or clothing. The detergent composition is typically a non-buffered composition that contains one or more C12 surfactants, typically at least a sodium lauroyl sarcosinate and the detergent composition is typically free of one or more of (1) any nonylphenol ethoxylate; (2) any pharmaceutically active drug or prodrug; (3) any salt in an amount that affects the functional characteristics of either of the solely C12 surfactants; (4) any salt in granular form; and/or (5) any ethoxylate that is a stand-alone ingredient.

Abstract: A composition and a method of washing urushiol off the surface of human skin. The composition includes a first solely C12 surfactant and a second solely C12 surfactant that are each in a non-buffered composition and the composition is free of each of the following: (1) any nonylphenol ethoxylate, (2) any pharmaceutically active drug or prodrug, or (3) any salt that affects the functional characteristics of either of the solely C12 surfactants.

Abstract: An isothiocyanate functional surfactant, wherein the protonated form of said surfactant is represented by the following chemical structure: wherein X includes an integer ranging from approximately 1 to approximately 25, and wherein Y includes an integer ranging from approximately 6 to approximately 25.

Abstract: A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition.

Abstract: A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease.

Abstract: A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer.

Abstract: A formulation, including: (a) a first medicament, wherein the first medicament includes an isothiocyanate functional compound/surfactant; and (b) a second medicament, wherein the second medicament includes an antineoplastic agent, such as a cytotoxic antineoplastic agent and/or a targeted antineoplastic agent.

Abstract: A method for treating psoriasis including the steps of applying an isothiocyanate functional surfactant to an area affected by psoriasis, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

Abstract: An isothiocyanate functional surfactant, wherein the protonated form of the surfactant includes the structure of formula (IA): wherein R1 includes the structure of formula (IIA), (IIIA), or (IVA), wherein X includes an integer ranging from approximately 0 to approximately 20, wherein R2 comprises a linear or branched aliphatic group containing approximately 8 to approximately 25 carbon atoms, and wherein R3 comprises an aliphatic or aromatic group containing approximately 1 to approximately 20 carbon atoms and at least one —N?C?S group.

Abstract: The present invention relates to methods and compositions for the prevention and treatment of keratin-based skin diseases. In particular, the application describes compositions and methods of treating a patient suffering from skin blistering comprising the use of phase II enzyme inducers and/or activity modifiers.

Abstract: The present invention relates to methods, formulations, and compositions for the treatment of biofilms. In particular, the application discloses isothiocyanate functional surfactants either alone or combination with adjunct agents to treat biofilms.

Abstract: A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

Abstract: A detergent composition and a method of washing/cleaning urushiol at least partially, more typically substantially or completely off a surface of human skin or clothing. The detergent composition is typically a non-buffered composition that contains one or more C12 surfactants, typically at least a sodium lauroyl sarcosinate and the detergent composition is typically free of one or more of (1) any nonylphenol ethoxylate; (2) any pharmaceutically active drug or prodrug; (3) any salt in an amount that affects the functional characteristics of either of the solely C12 surfactants; (4) any salt in granular form; and/or (5) any ethoxylate that is a stand-alone ingredient.

Abstract: A composition and a method of washing urushiol off the surface of human skin. The composition includes a first solely C12 surfactant and a second solely C12 surfactant that are each in a non-buffered composition and the composition is free of each of the following: (1) any nonylphenol ethoxylate, (2) any pharmaceutically active drug or prodrug, or (3) any salt that affects the functional characteristics of either of the solely C12 surfactants.

Abstract: An isothiocyanate functional surfactant, wherein the protonated form of said surfactant is represented by the following chemical structure: wherein X includes an integer ranging from approximately 1 to approximately 25, and wherein Y includes an integer ranging from approximately 6 to approximately 25.

Abstract: A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition.

Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

Abstract: A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer.

Abstract: A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease.

Abstract: A formulation, including: (a) a first medicament, wherein the first medicament includes an isothiocyanate functional compound/surfactant; and (b) a second medicament, wherein the second medicament includes an antineoplastic agent, such as a cytotoxic antineoplastic agent and/or a targeted antineoplastic agent.